



FOR IMMEDIATE RELEASE

Sun Pharma to announce first quarter results on August 03, 2023

July 17, 2023, Mumbai: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will announce results for the first quarter ending June 30, 2023 on August 03, 2023. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (06.30 pm IST, August 03, 2023)

The Company will conduct an hour-long call at 06.30 pm IST on August 03, 2023 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please pre-register yourself on below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Earnings release	August 03, 2023	www.sunpharma.com
Earnings conference call	06.30 pm IST, August 03, 2023	Universal Number: +91 22 6629 0049 +91 22 7194 5729 Via audio webcast, details of which will be made available on www.sunpharma.com
Pre-registration details (to avoid wait time)		Click here for DiamondPassRegistration
Replay of conference call	August 03, 2023 to August 10, 2023	India: +91 22 7194 5757 Code: 88366 Via audio webcast playback, details of which will be made available on www.sunpharma.com

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is a leading global pharmaceutical company with specialty and generic presence in world's largest pharma markets. It is India's largest pharma company, 10th largest generic company in the US, one of the largest Indian pharma companies across Emerging Markets and markets a broad specialty portfolio globally including US. Its specialty business has grown 24% CAGR since 2018 with key marketed products across dermatology, ophthalmology and oncology. Sun's generics operations are vertically integrated and deliver high-quality products at affordable prices, trusted by physicians, customers and patients in over 100 countries. Its manufacturing facilities span across six continents and are approved by multiple regulatory agencies. Sun Pharma fosters research capabilities across six major global R&D centers. Sun is proud of its multi-cultural workforce comprising over 50 nationalities. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live.

Contacts:

Investors:

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail Gaurav.chugh@sunpharma.com